Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Summary

To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease

Timeline

Start

2022-08-24

Primary completion

2023-07-25

Completion

2023-07-25

Outcome

Outcome not reported

Stopped: “PI Request”

Drugs

Indications